In plain language
In one electrophysiology lab, switching to a newer fluoroscopy system set up for low dose cut patient dose area product by about 91% without longer procedures or lower success. Staff dose was not measured directly.
At a glance
- Type of study
- Original research, Retrospective cohort study
- Who was studied
- Patients
- Summary based on
- the abstract
What it found
Overall dose area product fell by 91% with the new optimized fluoroscopy system compared with the older system.
Key figures: 91% (5.0 [2.0-17.0] to 0.45 [0.16-2.61] Gycm2 [P > 0.001])
Fluoroscopy times, acquisitions, procedural times and success were largely similar between systems.
Dose-area product (DAP) values with the new system were among the lowest published for all procedure groups.
Limits to keep in mind
Single-centre before-after comparison over two consecutive years, so practice changes and case mix may confound results; only patient DAP was measured, not staff dose.
Related research summaries
- Fluoroscopy-minimization strategy for catheter ablation of Supraventricular Tachycardia by wOmen OPerators: the STOOP Multicentre Registry (2026, Prospective cohort study)
- Two Central Nervous System Tumors in One Catheter Lab: Time to Rethink Radiation Protection (2026, Retrospective cohort study)
- Radiation Awareness for EVAR in Hybrid Operating Room: An Instant Operator Risk Chart (2021, Dosimetry measurement study)
- Utilization of a Radiation Safety Time-Out Reduces Radiation Exposure During Electrophysiology Procedures (2019, Prospective cohort study)
- Completely nonfluoroscopic catheter ablation of left atrial arrhythmias and ventricular tachycardia (2018, Case report or series)
How this summary was made
ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.
Prepared November 3, 2026.